Those individuals referred for enrollment in the ADRC on average progressed earlier on amyloid and tau PET compared to those in the MCSA, which in part is due to the presence of individuals with early-onset AD in the ADRC. The gene discussed is MAPT; the disease is Alzheimer disease.